欧洲杯竞猜手机app

Asset-light operations
fully control the high-profit links of the industry chain

HOME >R&D PLATFORM >THE FIELD OF SMALL MOLECULE DRUGS

THE FIELD OF SMALL MOLECULE DRUGS

Sichuan shangrui biomedical Co., Ltd. was established in June 2008. Since its establishment, it has been committed to the research and development of generic chemicals, mainly in the fields of analgesia and hypertension. The R & D team has strong R & D strength, and has obtained 4 production approval documents and several clinical approval documents. While focusing on R & D, the company also attaches great importance to intellectual property protection. It has applied for a number of invention patents related to products, and three of them have been authorized. At present, the R & D team has more than 30 people, and a special R & D quality assurance officer has been set up to supervise the compliance of the R & D process, and a complete quality assurance system has been established. At the same time, relying on the current drug management laws and regulations, the company's operation mode began to shift from the original commissioned production of varieties settled down to the commissioned production enterprise as the variety listing license holder. Now one variety has been declared as a listing permit holder, and more varieties will be declared in this way in the future. We believe that as long as we adhere to the company's concept of "pragmatic, enterprising" and do a solid job in the basic research and development of each product, we will achieve the win-win goal with each partner as soon as possible.

网站地图网站地图
友情链接:欧洲杯竞彩国外网站  欧洲杯正规下单平台  欧洲杯竞彩平台推荐  欧洲杯投注网  欧洲杯买球APP  欧洲杯足球购买渠道在哪  欧洲杯买球APP  欧洲杯投注网  欧洲杯可以买球的  欧洲杯竞彩平台推荐  欧洲杯球赛在哪里买  欧洲杯正规下单平台  欧洲杯买球APP  欧洲杯外围竞猜  欧洲杯竞彩平台推荐  欧洲杯线上买球  欧洲杯app排行榜前十名  欧洲杯投注网  欧洲杯外围竞猜  欧洲杯app排行榜前十名